Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in Metastatic CRPC with Correlative Assessment
NCT01942837Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2013
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Dana-Farber Cancer Institute. Started Sep 2013; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01942837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01942837.